Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
9 hedge funds and large institutions have $780K invested in Rosetta Genomics Ltd. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
10% less funds holding
Funds holding: 10 → 9 (-1)
30% less capital invested
Capital invested by funds: $1.11M → $780K (-$329K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23.4K |
| 3 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$280 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$33.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$705 |
ROSG Hedge Fund Activity: Q3 2016 in Review
9 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2016, worth a combined $780K — down 30% from $1.11M a quarter earlier.
Fund positioning in ROSG was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $44.6K. The largest seller was Highlander Capital Management, cutting an estimated $33.9K.
- 9 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2016, down from 10 in Q2 2016.
- Funds reported $780K of Rosetta Genomics Ltd. stock for Q3 2016, down 30% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Rosetta Genomics Ltd. buyer in Q3 2016 was Morgan Stanley, an estimated $44.6K added.
- The largest Rosetta Genomics Ltd. seller in Q3 2016 was Highlander Capital Management, an estimated $33.9K sold.
Based on aggregated 13F filings for Q3 2016.